Published in AIDS Weekly, October 29th, 2007
This indication is based on analyses of plasma HIV-1 RNA levels up through 24 weeks in two controlled studies of ISENTRESS (pronounced i-sen-tris). These studies were conducted in clinically advanced, three-class antiretroviral (nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.